Dengue: knowledge gaps, unmet needs, and research priorities
Dengue virus is a mosquito-borne pathogen that causes up to about 100 million cases of
disease each year, placing a major public health, social, and economic burden on …
disease each year, placing a major public health, social, and economic burden on …
Historical perspectives on flavivirus research
MR Holbrook - Viruses, 2017 - mdpi.com
The flaviviruses are small single-stranded RNA viruses that are typically transmitted by
mosquito or tick vectors. These “arboviruses” are found around the world and account for a …
mosquito or tick vectors. These “arboviruses” are found around the world and account for a …
Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
The first approved dengue vaccine has now been licensed in six countries. We propose that
this live attenuated vaccine acts like a silent natural infection in priming or boosting host …
this live attenuated vaccine acts like a silent natural infection in priming or boosting host …
The impact of the newly licensed dengue vaccine in endemic countries
M Aguiar, N Stollenwerk… - PLoS neglected tropical …, 2016 - journals.plos.org
Background With approximately 3 billion people at risk of acquiring the infection, dengue
fever is now considered the most important mosquito-borne viral disease in the world, with …
fever is now considered the most important mosquito-borne viral disease in the world, with …
The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model …
Background Large Phase III trials across Asia and Latin America have recently
demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) …
demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) …
Protective and immunological behavior of chimeric yellow fever dengue vaccine
SB Halstead, PK Russell - Vaccine, 2016 - Elsevier
Clinical observations from the third year of the Sanofi Pasteur chimeric yellow fever dengue
tetravalent vaccine (CYD) trials document both protection and vaccination-enhanced …
tetravalent vaccine (CYD) trials document both protection and vaccination-enhanced …
Virus like particles (VLP) as multivalent vaccine candidate against chikungunya, Japanese encephalitis, yellow fever and zika virus
Mosquito borne viral diseases are an emerging threat as evident from the recent outbreak of
Zika virus (ZIKV) as well as repeated outbreaks of Chikungunya (CHIKV), Yellow fever (YFV) …
Zika virus (ZIKV) as well as repeated outbreaks of Chikungunya (CHIKV), Yellow fever (YFV) …
[HTML][HTML] Reviewing estimates of the basic reproduction number for dengue, Zika and chikungunya across global climate zones
Y Liu, K Lillepold, JC Semenza, Y Tozan… - Environmental …, 2020 - Elsevier
Abstract Background Globally, dengue, Zika virus, and chikungunya are important viral
mosquito-borne diseases that infect millions of people annually. Their geographic range …
mosquito-borne diseases that infect millions of people annually. Their geographic range …
Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
SB Halstead - Human vaccines & immunotherapeutics, 2018 - Taylor & Francis
ABSTRACT A tetravalent live-attenuated 3-dose vaccine composed of chimeras of yellow
fever 17D and the four dengue viruses (CYD, also called Dengvaxia) completed phase 3 …
fever 17D and the four dengue viruses (CYD, also called Dengvaxia) completed phase 3 …
Ethics of a partially effective dengue vaccine: Lessons from the Philippines
SB Halstead, LC Katzelnick, PK Russell, L Markoff… - Vaccine, 2020 - Elsevier
Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur
is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was …
is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was …